← Back to Search

TMS for Post-Traumatic Stress Disorder

N/A
Recruiting
Led By Sanne van Rooij, PhD
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Capable and willing to provide informed consent
Men and women 18-65 years of age
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, day 10
Awards & highlights

Study Summary

This trial will study whether a TMS treatment can improve symptoms of PTSD and related biological markers in a population that doesn't have access to many resources.

Who is the study for?
This trial is for men and women aged 18-65 with partial PTSD, including specific symptoms of heightened arousal and reactivity. Participants must be able to consent, follow the treatment schedule, have not had TMS before, no history of certain mental or neurological disorders, stable on current medications if any, no recent substance abuse or other clinical study participation.Check my eligibility
What is being tested?
The study tests whether TMS can improve PTSD symptoms and biological markers like brain function and startle responses. It aims to identify new brain targets for TMS therapy in PTSD patients while also understanding individual differences to personalize future treatments.See study design
What are the potential side effects?
TMS may cause discomfort at the stimulation site, headache, lightheadedness or seizures in rare cases. Some individuals might experience brief alterations in hearing or mood changes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am able and willing to agree to the study's procedures.
Select...
I am between 18 and 65 years old.
Select...
I have partial PTSD with increased arousal and reactivity.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, day 10
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, day 10 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Amygdala Reactivity during fear processing pre- to post-treatment
Wounds and Injuries
Secondary outcome measures
Change in Fear-Potentiated Startle Responses to danger and safety cues pre- to post-treatment.
Change in Post-traumatic stress disorder (PTSD) hyperarousal symptoms pre- to post-treatment
Change in discrimination between danger and safety cues pre- to post-treatment
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Transcranial Magnetic Stimulation (TMS)Experimental Treatment1 Intervention
TMS is a noninvasive treatment that uses magnetic fields to induce a small electric current in specific brain regions.
Group II: Sham Transcranial Magnetic Stimulation (TMS)Placebo Group1 Intervention
Sessions of Sham Transcranial Magnetic Stimulation (TMS) will be conducted.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Magnetic Stimulation (TMS)
2018
Completed Phase 4
~570

Find a Location

Who is running the clinical trial?

Emory UniversityLead Sponsor
1,638 Previous Clinical Trials
2,560,452 Total Patients Enrolled
National Institute of Mental Health (NIMH)NIH
2,784 Previous Clinical Trials
2,689,197 Total Patients Enrolled
Sanne van Rooij, PhDPrincipal Investigator - Emory University
Emory University

Media Library

Transcranial Magnetic Stimulation (TMS) Clinical Trial Eligibility Overview. Trial Name: NCT04563078 — N/A
Post-Traumatic Stress Disorder Research Study Groups: Transcranial Magnetic Stimulation (TMS), Sham Transcranial Magnetic Stimulation (TMS)
Post-Traumatic Stress Disorder Clinical Trial 2023: Transcranial Magnetic Stimulation (TMS) Highlights & Side Effects. Trial Name: NCT04563078 — N/A
Transcranial Magnetic Stimulation (TMS) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04563078 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open slots for enrolment in this trial?

"Affirmative. According to clinicaltrials.gov, recruitment for this research project is still ongoing since it was posted on February 15th 2021 and last edited on January 31st 2022. 80 volunteers are required from one centre."

Answered by AI

Is this trial open to individuals over the age of sixty?

"This medical trial is available to people aged 18-65. For those younger than 18, 46 are trials exist and for seniors over 65, there are 329 studies taking place."

Answered by AI

What are the end goals of this experiment?

"This clinical trial aims to measure the variation in skin conductance response to trauma cues from baseline to day 10. Secondary objectives include quantifying changes of Fear-Potentiated Startle Responses for both danger and safety signals, as well as alterations of inhibition-related activation within the ventromedial prefrontal cortex (vmPFC) and hippocampus pre- and post-treatment."

Answered by AI

Are there any eligibility criteria to participate in this research?

"This research project is searching for 80 individuals, aged 18-65, exhibiting signs of post traumatic stress disorder. As per the DSM-5 criteria using CAPS-5 and with at least 3 out of 4 symptom clusters (cluster E being one), participants must be able to give informed consent and comply with treatment protocol."

Answered by AI

How many participants are currently enrolled in this experiment?

"Affirmative. Data hosted on clinicaltrials.gov attests that this healthcare research, which was first unveiled on February 15th 2021, is still searching for participants. Around 80 individuals must be identified from 1 different medical facility."

Answered by AI

Who else is applying?

What state do they live in?
Tennessee
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Effect of TMS on PTSD Biomarkers
Sanne van Rooij 2021. "Effect of TMS on PTSD Biomarkers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04563078.
~18 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top